C-fos Dusp1
C-fos Dusp1 - Related Videos
10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
0 Views •
2019
Here, we describe protocols for the genetic and chemical validation of c-Fos and Dusp1 as a drug target in leukemia using in vitro and in vivo genetic and humanized mouse models. This method can be applied to any target for genetic validation and therapeutic development.
08:07
Simultaneous Detection of c-Fos Activation from Mesolimbic and Mesocortical Dopamine Reward Sites Following Naive Sugar and Fat Ingestion in Rats
0 Views •
Cited by 24 •
2016
The goal of this study is to identify reward-related distributed brain networks by delineating a reliable immunohistological technique using cellular c-fos activation to measure simultaneous changes in dopamine pathways and terminal sites after novel ingestion of fat and sugar in rats.
05:44
The c-FOS Protein Immunohistological Detection: A Useful Tool As a Marker of Central Pathways Involved in Specific Physiological Responses In Vivo and Ex Vivo
0 Views •
Cited by 44 •
2016
Here, we present a protocol based on c-FOS protein immunohistological detection, a classical technique used for the identification of neuronal populations involved in specific physiological responses in vivo and ex vivo.
08:37
Fluorescence Activated Cell Sorting (FACS) and Gene Expression Analysis of Fos-expressing Neurons from Fresh and Frozen Rat Brain Tissue
0 Views •
Cited by 34 •
2016
Here we present a Fluorescence Activated Cell Sorting (FACS) protocol to study molecular alterations in Fos-expressing neuronal ensembles from both fresh and frozen brain tissue. The use of frozen tissue allows FACS isolation of many brain areas over multiple sessions to maximize the use of valuable animal subjects.
08:56
Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
0 Views •
Cited by 1 •
2022
The present protocol describes a detailed benchtop catalytic method that yields a unique borylated derivative of...
FAQs
ERK signaling can stimulate C-FOS transcription, providing a readout of pathway-responsive gene activation. DUSP1 acts later in the same signaling context by encoding a phosphatase that removes phosphate groups from MAPK proteins and reduces their activity. Examining both genes therefore links pathway stimulation with its built-in attenuation, rather than treating either marker as an isolated signal.
Because both genes respond rapidly to extracellular signals, their expression or protein levels can change substantially during an experiment. A measurement captures the relationship between stimulus exposure and cellular response at one time point, not a permanent state. Comparing appropriately timed samples helps distinguish pathway activation, feedback attenuation, and later changes in tumor cell behavior.
C-FOS primarily indicates transcriptional responsiveness associated with signaling such as ERK activation, whereas DUSP1 reflects a feedback mechanism that can dampen MAPK activity. Using them together can provide a more informative picture than relying on one marker: C-FOS may indicate pathway engagement, while DUSP1 helps reveal the accompanying regulatory response.
The same marker pattern may not have identical meaning in every biological setting. Cell type influences how extracellular signals are processed, and the initiating stimulus affects whether the response is associated with stress, proliferation, or another change in tumor cell behavior. Results should therefore be interpreted with the experimental context, stimulus, and sampling time considered together.
Researchers assess these responses by measuring gene expression or protein levels and then relating the results to pathway activity or cellular behavior. Expression data can indicate transcriptional responses, while protein measurements show changes at the protein level. Parallel assessment of both markers may help evaluate signaling activation, feedback control, stress responses, or proliferation-related effects.
The pair is useful when a study needs to connect oncogenic signaling with regulatory feedback and phenotypic consequences. Investigators may examine both during studies of pathway activation, altered tumor cell behavior, drug mechanisms, or treatment response. Their combined pattern can help determine whether an intervention changes signaling activity, its attenuation, or both.
Changes in C-FOS or DUSP1 expression and protein levels can provide molecular evidence that a treatment affects signaling pathways or cellular responses. A combined analysis may show whether the intervention influences pathway activation and the feedback that limits MAPK activity. These measurements support treatment-response and drug-mechanism studies, but interpretation remains dependent on cell type and timing.